Shen Lee Bridgitte, Pizzicato Lia, Langford Elizabeth, Shi Liucheng, Divino Victoria, Alexander Adam, Nair Abhishek A
Vision Optique, Houston, TX, USA.
Real World Solutions, IQVIA, Falls Church, VA, USA.
Clin Ophthalmol. 2025 Jul 31;19:2529-2540. doi: 10.2147/OPTH.S529837. eCollection 2025.
To characterize early adopters of perfluorohexyloctane (PFHO) and 90-day refill rates after the first prescription, overall and compared to a cohort initiating cyclosporine ophthalmic emulsion 0.05% (CsA).
Patients ≥18 years newly initiating PFHO or CsA between September and November 2023 were identified in IQVIA open-source medical and pharmacy claims databases (date of first claim = index date). Demographics, index prescription characteristics, 12-month baseline clinical characteristics, and 90-day refill rates were descriptively compared between cohorts. A multivariable logistic regression model was developed to evaluate factors associated with the adjusted odds of 90-day refill of the respective index therapy.
The final sample included 7,209 PFHO and 75,871 CsA patients (mean age: 60.6 and 66.6 years; 79.9% and 80.4% female; 67.0% and 39.4% third party payer; respectively). In total, 75.9% of PFHO patients received their prescription through the mail while 92.2% of CsA patients received it through the retail setting. Only 38.5% of PFHO and 33.3% of CsA patients had a diagnosis of dry eye disease (DED) over the 12-month baseline period. Nearly half (46.6%) of PFHO patients used at least one different DED medication over the 12-month baseline compared to 8.1% of CsA patients. Over the 90-day follow-up, most (72.0%) PFHO patients refilled the prescription for their index therapy compared to 37.4% of CsA patients. In the multivariable logistic regression model, PFHO patients had 72% higher likelihood of refilling their index prescription within 90-days compared to CsA patients (adjusted odds ratio: 1.72; 95% confidence interval: 1.60-1.86).
High DED medication use among PFHO patients in the 12-month period prior to treatment initiation suggests that prior medication may not have resolved their DED symptoms. The higher 90-day refill rate for PFHO versus CsA indicates a higher degree of patient satisfaction with this new, first-in-class treatment for DED.
对全氟己基辛烷（PFHO）的早期采用者以及首次处方后的90天再填充率进行特征描述，总体情况并与开始使用0.05%环孢素眼用乳剂（CsA）的队列进行比较。
在IQVIA开源医疗和药房索赔数据库中识别出2023年9月至11月期间新开始使用PFHO或CsA的18岁及以上患者（首次索赔日期=索引日期）。对队列之间的人口统计学、索引处方特征、12个月基线临床特征和90天再填充率进行描述性比较。建立多变量逻辑回归模型以评估与各自索引治疗90天再填充的调整后几率相关的因素。
最终样本包括7209例PFHO患者和75871例CsA患者（平均年龄：60.6岁和66.6岁；女性分别为79.9%和80.4%；第三方付款人分别为67.0%和39.4%）。总体而言，75.9%的PFHO患者通过邮寄方式获得处方，而92.2%的CsA患者通过零售途径获得。在12个月的基线期内，只有38.5%的PFHO患者和33.3%的CsA患者被诊断为干眼病（DED）。在12个月的基线期内，近一半（46.6%）的PFHO患者使用了至少一种不同的DED药物，而CsA患者为8.1%。在90天的随访中，大多数（72.0%）PFHO患者为其索引治疗重新开了处方，而CsA患者为37.4%。在多变量逻辑回归模型中，与CsA患者相比，PFHO患者在90天内重新开具索引处方的可能性高72%（调整后的优势比：1.72；95%置信区间：1.60 - 1.86）。
在开始治疗前的12个月期间，PFHO患者中DED药物的高使用率表明先前的药物治疗可能未解决他们的DED症状。PFHO与CsA相比更高的90天再填充率表明患者对这种新的、一流的DED治疗的满意度更高。
